-
FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’
#CLR131 for the Treatment of#Rhabdomyosarcoma - https://bit.ly/2kP5Xka pic.twitter.com/VT4QChMU2p
-
CLR131 achieves fast track designation from FDA for relapsed myeloma and DLBCL. A phospholipid drug conjugate (PDC) which targets iodine-131 to cancer cells. Interesting to see how it fares against bispecifics and ADCs. https://www.cellectar.com/news-media/press-releases/detail/211/cellectar-receives-fda-fast-track-designation-for-clr-131 …
#CLR131@CellectarBiopic.twitter.com/UX4tH4a3Gt
-
saw jpm17. Could be prom. tech.,
#CLR131 first data good. Biggest problem: they are moving far too slow bec of very low cash. -
$CLRB#CLR131 can't find a scientific publication where your statement'PFS better than with dara'is http://confirmed.Link pls -
$CLRB buy the dips leading to 2nd quarter 2019, Routing for successful phase 2 top line data.#CLR131#cancer#multiplemyeloma#myeloma#pennystocks#Nasdaqpic.twitter.com/UUXBmz124L
Prikaži ovu nit -
Hi there! Any new information about
#CLR131 or the company in general can be found on our website and in our corporate presentation. Thanks for your question! https://www.cellectar.com/news-media/presentations … -
@CellectarBio this is the way to make investors loose trust. Or do you have another argumention why you omitted a patient from response rate calculation for#clr131 and did not mention it?Prikaži ovu nit -
$CLRB#ICYMI: Cellectar Biosciences to Host a#CLR131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020 http://bit.ly/2R4I5bW#mmsm#clinicaltrialspic.twitter.com/NsOj9ro9LJ -
Design for NCI-Supported Phase II Study of
#CLR131 in Multiple#Myeloma and Other Hematologic Malignancies$CLRB http://www.1stoncology.com/blog/cellectar-biosciences-announces-design-for-nci-supported-phase-ii-study-of-clr-131-in-multiple-myelomaother-hematologic-malignancies … -
Successful Cohort 3 and Start of Cohort 4 In Phase I Study of
#CLR131 In Patients With R/R Multiple#Myeloma http://www.1stoncology.com/blog/upon-successful-completion-of-cohort-3-cellectar-biosciences-initiates-fourth-cohort-of-its-phase-i-clinical-trial-of-clr-131-in-multiple-myeloma … -
$CLRB Do you have our upcoming clinical data call on your calendar yet? If not, click the link for more information about the call: http://bit.ly/2u1gRLH For more info about#CLR131, visit http://bit.ly/31hOPIt#mmsm#ThursdayThoughtspic.twitter.com/Yu7E4yDsY6
-
$CLRB “...drop the payload internally, inside of the cell. It’s the ultimate Trojan Horse, if you will, when you think about our delivery platform.” http://bit.ly/30fUIoX#mmsm#CLR131#WednesdayWisdompic.twitter.com/pdeQicRKX4 -
#CellectarBiosciences Announces $2 Million NCI SBIR Contract for a Phase 2 Clinical Study of#CLR131 http://www.1stoncology.com/blog/cellectar-biosciences-announces-2-million-nci-sbir-contract-for-a-phase-2-clinical-study … -
Fractionated Dosing of
#CLR131 in Patients with Relapsed or Refractory#MultipleMyeloma Presented at#ASH19$CLRB http://www.1stoncology.com/blog/fractionated-dosing-of-clr-131-in-patients-with-relapsedrefractory-multiple-myeloma-presented-at-the-61st-annual-american-society-of-hematology-conference1234552109 … -
$CLRB "...this is a unique option for those with MM... CLR 131 falls into a niche category for patients with MM... This is a whole new therapeutic option for [these] patients” http://bit.ly/2Bh2283#CLR131#mmsm#ClinicalTrialsSaveLives pic.twitter.com/LzYAmepY2T
-
$CLRB Recent Key#Accomplishments and Third Quarter Financial Results http://bit.ly/2eOcpWi#MultipleMyeloma#HemOnc#CLR131 pic.twitter.com/vPNvMS5xQV
-
#CellectarBiosciences Receives Japanese Patent for#CLR131 and#CLR125 for the Treatment of#CancerStemCells http://www.1stoncology.com/blog/cellectar-biosciences-receives-japanese-patent-for-clr-131clr-125-for-the-treatment-of-cancer-stem-cells … -
$CLRB From the@cure_magazine interview with Dr. Laura Finn: “What I like about this drug, and especially in multiple myeloma, is its safety and its very low incidence of side effects.” http://bit.ly/2pA4WCK#CLR131#ClinicalTrials#mmsmpic.twitter.com/nCJiOvvG6h
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.